<h1>Genomics company acquires proteomics leader for $350M cash plus $75M performance payments</h1> A genomics company announced a definitive agreement to acquire a proteomics technology leader for $350 million cash plus up to $75 million in performance-based payments. The transaction combines complementary proteomics expertise with the acquirer's sequencing platforms and global reach to advance multiomics strategy. The companies have partnered since 2021 on co-development projects. The acquisition includes approximately 250 employees and facilities in Colorado, with the business expected to become profitable by 2027. Transaction completion requires regulatory clearance and is anticipated in the first half of 2026.